Definium Therapeutics (DFTX) Cash from Financing Activities (2019 - 2026)

Definium Therapeutics (DFTX) has 8 years of Cash from Financing Activities data on file, last reported at $5.3 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 429.84% year-over-year to $5.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $271.6 million (up 219.69% YoY) and the FY2025 annual result came in at $267.3 million, up 5.56% from the prior year.
• Cash from Financing Activities declined to $5.3 million in Q1 2026 per DFTX's latest filing, from $245.9 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $245.9 million in Q4 2025 and bottomed at -$166000.0 in Q1 2022.
• The 5-year median for Cash from Financing Activities is $3.8 million (2024), against an average of $35.7 million.
• The widest annual swing landed in 2022, when Cash from Financing Activities plunged 100.18%; it then soared 28930.36% in 2024.
• Tracing DFTX's Cash from Financing Activities over 5 years: stood at $416000.0 in 2022, then soared by 523.32% to $2.6 million in 2023, then jumped by 46.82% to $3.8 million in 2024, then soared by 6358.31% to $245.9 million in 2025, then slumped by 97.84% to $5.3 million in 2026.
• Per Business Quant, the three latest DFTX Cash from Financing Activities figures stand at $5.3 million (Q1 2026), $245.9 million (Q4 2025), and $749000.0 (Q3 2025).

Peer Comparison